Daiichi Sankyo Announces First European Approval For Sevikar HCT(R), A New Three-in-one Combination Product For The Treatment Of High Blood Pressure
http://www.medilexicon.com/medicalnews.php?newsid=230289
Daiichi Sankyo Europe announced that Sevikar HCT® is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). This new drug combines the three widely prescribed blood pressure treatments olmesartan medoxomil, amlodipine, and hydrochlorothiazide (HCT) in one single pill to help effectively control hypertension.
http://www.medilexicon.com/medicalnews.php?newsid=230289
Daiichi Sankyo Europe announced that Sevikar HCT® is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). This new drug combines the three widely prescribed blood pressure treatments olmesartan medoxomil, amlodipine, and hydrochlorothiazide (HCT) in one single pill to help effectively control hypertension.
